scholarly journals Evaluation of Glycemic Control in Type 1 Diabetic Patients after Switching from Conventional Long-acting Insulin to Insulin Degludec

2016 ◽  
Vol 42 (8) ◽  
pp. 562-568
Author(s):  
Yuriko Sugiyama ◽  
Mai Ikemura ◽  
Satoshi Okusada ◽  
Toshio Iwakura ◽  
Tohru Hashida
Keyword(s):  
Glycemic Control ◽  
Insulin Degludec ◽  
Diabetic Patients ◽  
Acting Insulin ◽  
Long Acting ◽  
Type 1 Diabetic Patients

scholarly journals Insulin degludec is a new ultra-long-acting insulin analogue

2014 ◽  
Vol 17 (2) ◽  
pp. 91-104 ◽  
Author(s):  
Ivan Ivanovich Dedov ◽  
Marina Vladimirovna Shestakova
Keyword(s):  
Glycemic Control ◽  
Insulin Glargine ◽  
Insulin Analogue ◽  
Insulin Analogues ◽  
Insulin Degludec ◽  
Treat To Target ◽  
Nocturnal Hypoglycaemia ◽  
Acting Insulin ◽  
Long Acting

Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia as compared to NPH insulin. However, fear of hypoglycaemia and weight gain, as well as the complexity of regimen, are still the most important barriers to well-timed initiation and intensification of insulin therapy. Insulin degludec (Tresiba?) is a new ultra-long-acting insulin analogue. After subcutaneous injection degludec forms repository of soluble multi-hexamers, which are gradually absorbed to the bloodstream, providing a flat, stable antihyperglycemic effect lasting more than 42 h, and low intra-individual variability as opposed to currently used basal insulin analogues, insulin glargine and insulin detemir. In the seven randomized, open label, controlled phase 3 trials lasting 26 or 52 weeks, using treat-to-target (no more) non-inferiority design, insulin degludec provided glycemic control similar to that of insulin glargine with lower risk of nocturnal hypoglycaemia and good safety profile in patients with type 1 or 2 diabetes. Furthermore, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes have shown that it is possible to vary the injection time without compromising glycemic control or safety of the therapy.

Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI

Endocrine ◽  
2013 ◽  
Vol 46 (2) ◽  
pp. 256-262 ◽  
Author(s):  
Maria Ida Maiorino ◽  
Giuseppe Bellastella ◽  
Michela Petrizzo ◽  
Maria Rosaria Improta ◽  
Clementina Brancario ◽  
...  
Keyword(s):  
Health Care ◽  
Glycemic Control ◽  
Treatment Satisfaction ◽  
Diabetic Patients ◽  
Pediatric Health ◽  
Pediatric Health Care ◽  
Type 1 Diabetic Patients

scholarly journals Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients

2006 ◽  
Vol 4 (3) ◽  
pp. 686-688 ◽  
Author(s):  
I. SELJEFLOT ◽  
J. R. LARSEN ◽  
K. DAHL-JORGENSEN ◽  
K. F. HANSSEN ◽  
H. ARNESEN
Keyword(s):  
Glycemic Control ◽  
Fibrinolytic Activity ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

Improved glycemic control with insulin aspart in type-1 diabetic patients using algorith-driven dose optimization

2000 ◽  
Vol 50 ◽  
pp. 78
Author(s):  
Gyula Tamas ◽  
Michel Marre ◽  
Ivan Dedov ◽  
Ricardo Astorga ◽  
Birgitte Hylleberg ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Insulin Aspart ◽  
Dose Optimization ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients
Sign in / Sign up

Export Citation Format

Share Document